Protagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024. In the quarter to June 2026, revenue grew 3,749.2%, EPS grew 549.1% and free cash flow grew 839.7%, each against the same quarter a year earlier.
Follow PTGX
Protagonist Therapeutics, Inc. (PTGX) P/E ratio
As of 16 October 2026, Protagonist Therapeutics, Inc. (PTGX) trades at a P/E ratio of 106×. Over the past ten years it has ranged from 0.0× (June 2026) to 130× (August 2026); the current reading is higher than 96% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 8.6× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 100× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 88.6× | 33.01% |
| 26 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CYTK Cytokinetics, Incorporated compare | n/m |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | n/m |
| AXSM Axsome Therapeutics, Inc. compare | n/m |
| TGTX TG Therapeutics, Inc. compare | 17.8× |
| KRYS Krystal Biotech, Inc. compare | 38.3× |
| CAI Caris Life Sciences,�Inc. compare | 81.3× |
| PTGX Protagonist Therapeutics, Inc. | 106× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)